Clinical feasibility of absorbable gelatin film adhesion barrier (GM142 "TENALEAF®") in gynecological laparoscopic surgery: Safety assessment for first-in-human use and surgical video.


Journal

The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 15 05 2022
accepted: 07 12 2022
pubmed: 29 12 2022
medline: 8 3 2023
entrez: 28 12 2022
Statut: ppublish

Résumé

To evaluate the safety and operability of the GM142 (TENALEAF®, Medical Division, Gunze Limited, Tokyo, Japan) adhesion barrier applied in patients undergoing surgery for benign gynecologic disease. This multicenter open study enrolled 34 patients from November 2018 to October 2019. The primary outcome was the incidence of adverse events (AE) within 12 weeks postoperatively. None of the 30 patients completing the study experienced a life-threatening AE. Thirteen patients (43.3%) suffered 30 mild or moderate AE in total. No intestinal obstruction (0/30) was observed, with the sample size justified by the AdSpray® trial (8/61 patients with AE). No gelatin-specific Immunoglobulin E (IgE) antibodies were induced in the patients. The adhesion barrier could be easily inserted (even via trocar) and positioned. After malfunctions were reported in six patients, the instructions for use were updated for trocar use. This study showed the safety and clinical feasibility GM142 as an adhesion barrier.

Identifiants

pubmed: 36577514
doi: 10.1111/jog.15527
doi:

Substances chimiques

gelatin film 0

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

980-987

Informations de copyright

© 2022 Japan Society of Obstetrics and Gynecology.

Références

Diamond MP, Freeman ML. Clinical implications of postsurgical adhesions. Hum Reprod Update. 2001;7:567-76.
Mercorio F, Mercorio A, Di Spiezo SA, Vencenzo Barba G, Pellicano M, Nappi C. Evaluation of ovarian adhesion formation after laparoscopic ovarian drilling by second-look minilaparoscopy. Fertil Steril. 2008;89:1229-33.
Dubuisson JB, Fauconnier A, Chapron C, Kreiker G, Nörgaard C. Second look after laparoscopic myomectomy. Hum Reprod. 1998;13:2102-6.
Stovall TG, Elder RF, Ling FW. Predictors of pelvic adhesions. J Reprod Med. 1989;34:345-8.
diZerega GS, Campeau JD. Peritoneal repair and post-surgical adhesion formation. Hum Reprod Update. 2001;7:547-55.
Arung W, Meurisse M, Detry O. Pathophysiology and prevention of postoperative peritoneal adhesions. World J Gastroenterol. 2011;17:4545-53.
Ten Broek RPG, Stommel MWJ, Strik C, van Laarhoven CJHM, Keus F, van Goor H. Benefits and harms of adhesion barriers for abdominal surgery: a systematic review and meta-analysis. Lancet. 2014;383:48-59.
Torii H, Takagi T, Urabe M, Tsujimoto H, Ozamoto Y, Miyamoto H, et al. Anti-adhesive effects of a newly developed two-layered gelatin sheet in dogs. J Obstet Gynaecol Res. 2017;43:1317-25.
Tsujimoto H, Tanzawa A, Matoba M, Hashimoto A, Suzuki S, Morita S, et al. The anti-adhesive effect of thermally cross-linked gelatin film and its influence on the intestinal anastomosis in canine models. J Biomed Mater Res B Appl Biomater. 2013;101:99-109.
Watanabe J, Yamaguchi S, Takemasa I, Yasui M, Hirano Y, Nakano D, et al. Safety, efficacy, and operability of a newly developed absorbable adhesion barrier (GM142) in patients with primary rectal cancer scheduled for diverting ileostomy during laparoscopic surgery: randomized controlled trial. Ann Gastroenterol Surg. 2022;6:515-22.
Suto T, Watanabe M, Endo T, Komori K, Ohue M, Kanemitsu Y, et al. The primary result of prospective randomized multicenter trial of new spray-type bio-absorbable adhesion barrier system (TCD-11091) against postoperative adhesion formation. J Gastrointest Surg. 2017;21:1683-91.
Cezar C, Korell M, Tchartchian G, Ziegler N, Senshu K, Herrmann A, et al. How to avoid risks for patients in minimal-access trials: avoiding complications in clinical first-in-human studies by example of the ADBEE study. Best Pract Res Clin Obstet Gynaecol. 2016;35:84-96.
Cezar C, Tchartchian G, Korell M, Ziegler N, Senshu K, de Wilde MS, et al. Long term follow-up concerning safety and efficacy of novel adhesion prophylactic agent for laparoscopic myomectomy in the prospective randomized ADBEE study. Best Pract Res Clin Obstet Gynaecol. 2016;35:97-112.
Takeuchi H, Kitade M, Kikuchi I, Shimanuki H, Kumakiri J, Takeda S. Influencing factors of adhesion development and the efficacy of adhesion-preventing agents in patients undergoing laparoscopic myomectomy as evaluated by a second-look laparoscopy. Fertil Steril. 2008;89:1247-53.
Takeuchi H, Kitade M, Kikuchi I, Shimanuki H, Kinoshita K. A novel instrument and technique for using Seprafilm hyaluronic acid/carboxymethylcellulose membrane during laparoscopic myomectomy. J Laparoendosc Adv Surg Tech A. 2006;16:497-502.
Ota K, Sato K, Ogasawara J, Takahashi T, Mizunuma H, Tanaka M. Safe and easy technique for the laparoscopic application of Seprafilm® in gynecologic surgery. Asian J Endosc Surg. 2019;12:242-5.
Huang YT, Su YY, Wu KY, Huang HY, Lin YS, Weng CH, et al. Learning curve analysis of applying Seprafilm hyaluronic acid/carboxymethylcellulose membrane during laparoscopic hysterectomy. Sci Rep. 2020;10:16592.
Ahmad G, O'Flynn H, Hindocha A, Watson A. Barrier agents for adhesion prevention after gynaecological surgery. Cochrane Database Syst Rev. 2015;2015(4):CD000475 Update in: Cochrane Database Syst Rev. 2020; Mar 22;3:CD000475.

Auteurs

Iwaho Kikuchi (I)

Medical Park Yokohama, Yokohama, Japan.

Mikio Momoeda (M)

Department of Integrated Women's Health, St. Luke's International Hospital, Tokyo, Japan.

Takafumi Ujihira (T)

Department of Obstetrics and Gynecology, Juntendo University Urayasu Hospital, Urayasu, Japan.

Michiyo Iguchi (M)

Medical Division, Gunze Limited, Tokyo, Japan.

Kaori Koga (K)

Department of Obstetrics and Gynecology, University of Tokyo, Tokyo, Japan.

Mineto Morita (M)

Department of Obstetrics and Gynecology, Toho University Omori Medical Center, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH